5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

The first half of 2023 saw the first approvals of therapies for a genetic subset of ALS and a pair of rare neurological disorders, Rett syndrome and Friedreich’s ataxia—and the regulator has several decisions for rare and orphan diseases on the docket in the second half of the year.